© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Lineage Cell Therapeutics, Inc. (LCTX) shows an Average True Range (ATR) of 0.1 and an Enterprise Value of 174.9M. Its average trading volume over the past 3 months is 1.89M, indicating liquidity. These fundamental metrics provide insight into LCTX's underlying financial health and market activity.
Lineage Cell Therapeutics, Inc. (LCTX) technical indicators as of December 22, 2025: the SMA 20 is -2.24%, SMA 50 at -3.59%, and SMA 200 at 52.53%. The RSI 14 value is 46.3, suggesting its current momentum. These technical analysis signals help assess LCTX's price trends and potential future movements.
Lineage Cell Therapeutics, Inc. (LCTX) stock performance overview as of December 22, 2025: The 52-week high is $2.09 (currently -19.62% below), and the 52-week low is $0.365 (currently 360.15% above). Over the past year, LCTX's performance is 232.02%, compared to the S&P 500's 12.87% change.
According to market data, Lineage Cell Therapeutics, Inc. (LCTX) stock's recent performance metrics show that over the last month, LCTX is -5.08%, with a Year-to-Date (YTD) performance of 234.33%. Over the past year, the stock has seen a 232.02% change. These figures summarize LCTX's price movements across various periods, reflecting its historical returns.
According to current financial data, LCTX stock's P/E (TTM) ratio is -5.68, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for LCTX, including P/S (35.73), P/B (18.49), and P/FCF (-18.71), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.